Merck’s KEYTRUDA & WELIREG combo shows breakthrough results in kidney cancer trial

Merck emphasized the broader significance of the findings

Pfizer and Astellas report groundbreaking results in muscle-invasive bladder cancer trial

Merck’s KEYTRUDA shows significant survival boost in platinum-resistant ovarian cancer

KEYTRUDA had previously met its primary endpoint of progression-free survival in all patients

Thermo Fisher launches genetic test to personalize transplant drug dosing

The TacroType test provides actionable genetic insights to help clinicians understand how individual patients metabolize tacrolimus

Novartis’ remibrutinib bags positive CHMP opinion for chronic urticaria

The oral therapy is aimed at adults with chronic spontaneous urticaria (CSU) who do not respond adequately to H1-antihistamines

Boehringer Ingelheim India and NIPER Raebareli join forces to boost pharma innovation

The MoU lays the groundwork for deep academic and research collaboration in pharmaceutical technologies

Promise Bio launches frontier Epiproteomic Innovation Grant to supercharge biotech R&D

The program offers selected participants advanced access to Promise Bio’s broad-epiproteomic platform

UK pours £20 million into cutting?edge tech to tackle drug & alcohol addiction

The funding comes under the AHG Catalysing Innovation Awards, part of the Addiction Healthcare Goals programme led by the Office for Life Sciences

AIM ImmunoTech advances Phase 2 pancreatic cancer trial with Ampligen and Imfinzi

The study is a collaboration between AIM, AstraZeneca, and Erasmus Medical Center in the Netherlands

FDA nod to AstraZeneca’s all-oral, fixed-duration therapy for CLL & SLL

The decision follows compelling data from the AMPLIFY Phase III trial, demonstrating that 77% of patients receiving the Calquence-venetoclax combination were progression-free at three years